Skip to main content

Table 2 A comparison of rheumatoid arthritis and psoriatic arthritis outcomes at biologic initiation, one year and 12 year reviews

From: Long-term remission and biologic persistence rates: 12-year real-world data

  Baseline 1 Year Review 12 Year Review
RA (n = 274) PsA (n = 129) p RA (n = 203) PsA (n = 96) p RA (n = 179) PsA (n = 87) p
Biologic
 Adalimumab 144 (52.6%) 47 (36.4%) 0.002 76 (44.7%) 27 (31.0%) 0.034 43 (25.6%) 28 (33.3%) NS
 Etanercept 100 (36.5%) 68 (52.7%) 0.002 62 (36.5%) 45 (51.7%) 0.019 48 (28.6%) 30 (35.7%) NS
 Infliximab 18 (6.6%) 14 (10.9%) NS 13 (7.6%) 11 (12.6%) NS 3 (1.8%) 8 (9.5%) 0.004
 Rituximab 12 (4.4%) 0 0.011 4 (2.4%) 0 NS 16 (9.5%) 0 0.004
 Othera 0 0   1 (0.6%) 0 NS 24 (14.3%) 8 (9.5%) NS
 None 0 0   14 (5.1%) 4 (3.1%) NS 34 (20.2%) 10 (11.9%) NS
Biologic persistence n/a n/a n/a 136 (49.6%) 76 (58.9%) NS 66 (38.2%) 45 (52.3%) NS
Methotrexate 176 (64.2%) 35 (27.3%) <0.001 108 (64.8%) 21 (24.4%) <0.001 72 (42.2%) 22 (25.9%) 0.008
PGH, mm 60 (0-100) 50 (0-100) NS 30 (0-100) 20 (0-90) <0.001 50 (0-100) 5 (0-100) <0.001
TJC28 9 (0-28) 6 (0-28) <0.001 1 (0-28) 0 (0-20) <0.001 0 (0-19) 0 (0-2) 0.019
SJC28 9 (0-28) 5 (0-28) <0.001 1 (0-28) 0 (0-25) <0.001 0 (0-15) 0 (0-2) <0.001
CRP, mg/L 16 (2-158) 9 (0-108) <0.001 4 (1-138) 4 (0-41) 0.034 3 (1-65) 2 (1-46) <0.001
Disease Activity
 Low 9 (3.5%) 13 (11.1%) 0.003 91 (55.2%) 60 (82.2%) <0.001 83 (79.8%) 22 (95.7%) NS
 Moderate 89 (34.4%) 65 (55.6%) <0.001 58 (35.2%) 10 (13.7%) 0.001 20 (19.2%) 1 (4.3%) 0.012
 High 160 (61.8%) 39 (33.3%) <0.001 16 (9.7%) 3 (4.1%) NS 1 (1%) 0 (0%) NS
Erosion progression 36 (28.1%) 5 (8.6%) 0.003 51 (31.9%) 12 (15.0%) 0.005
  1. PGH…Patient Global Health Visual Analogue Score (mm), TJC28..28-joint tender joint count, SJ28…28-joint swollen joint count aAlternative biologic or small molecule inhibitor-golimumab, certolizumab, tocilizumab, abatacept, secukinumab, ustekinumab, ixekizumab tofacitinib or baricitinib